November 2018 FDA Recall Drug by Breckenridge Pharmaceutical, Inc.
D-0279-2019 - Failed Stability Specifications

This Class III drug recall was voluntarily initiated by Breckenridge Pharmaceutical, Inc. on November 6, 2018 for the product Drug. The FDA reported the reason for recall as failed stability specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0279-2019

Reason for Recall
Failed Stability Specifications: Out-of-Specification results obtained for particle size distribution during stability testing.
Initiated
11-06-2018
Reported
11-21-2018
Quantity
9,193 bottles

Recall Profile & Regulatory Data

Class III - is a situation in which use of, or exposure to, a violative product is not likely to cause adverse health consequences.
Breckenridge Pharmaceutical, Inc.
Nationwide within the United States
Megestrol Acetate Oral Suspension, USP 625 mg/5mL, 150 mL bottle, Rx only, Distributed by: Breckenridge Pharmaceutical, Inc. Boca Raton, FL 33487, Manufactured by: Pharmaceutics International Inc. Hunt Valley, MD 21031

Batch or Lot Expiration Information

Lot# : 5599.008A, 5599.009A, 5599.010A, Exp. 04/2019; 5599.012A, 5599.013A, Exp. 11/2019; 5599.014A, Exp. 01/2020